Assignee
IMMUNEXT INC
US·8 granted patents·14 pending applications·44 citations·filing 2015–2025
Top patents by PatentIndex Score
22 records- 0193US12139532B2Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2017·Granted Nov 12, 2024·4 cites·14 claims
- 0292US11603403B2Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2017·Granted Mar 14, 2023·4 cites·11 claims
- 0391US11649283B2Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2017·Granted May 16, 2023·4 cites·24 claims
- 0491US10370455B2Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonistsIMMUNEXT INC·Filed 2015·Granted Aug 6, 2019·20 cites·14 claims
- 0590US11603402B2Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2017·Granted Mar 14, 2023·4 cites·9 claims
- 0690US2025263485A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2024·Application pending·0 cites
- 0787US11525000B2Anti-human VISTA antibodies and use thereofIMMUNEXT INC·Filed 2017·Granted Dec 13, 2022·4 cites·20 claims
- 0887US2025263484A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2024·Application pending·0 cites
- 0986US10874738B2Anti-CD154 antibody having improved binding, functional and safety characteristicsIMMUNEXT INC·Filed 2016·Granted Dec 29, 2020·3 cites·10 claims
- 1085US11596689B2Methods of immunosuppression comprising administering an anti-CD154 antibodyIMMUNEXT INC·Filed 2020·Granted Mar 7, 2023·1 cites·22 claims
- 1184US2024018238A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2023·Application pending·0 cites
- 1284US2025346666A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2025·Application pending·0 cites
- 1383US2024067719A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2022·Application pending·0 cites
- 1482US2024141037A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2023·Application pending·0 cites
- 1579US2022259310A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2022·Application pending·0 cites
- 1676US2021317206A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2021·Application pending·0 cites
- 1774US2021317207A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2021·Application pending·0 cites
- 1873US2024000929A1Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapyIMMUNEXT INC·Filed 2023·Application pending·0 cites
- 1961US2020199254A1Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonistsIMMUNEXT INC·Filed 2019·Application pending·0 cites
- 2054US2025108119A1NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFIMMUNEXT INC·Filed 2022·Application pending·0 cites
- 2151US2023310634A1Anti-human vista antibodies and use thereofIMMUNEXT INC·Filed 2021·Application pending·0 cites
- 2242US2019263931A1Anti-mct1 antibodies and uses thereofIMMUNEXT INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →